Rosa PoloXabier García‐AlbénizCarolina TeránMiguel MoralesDavid Rial‐CresteloMaría Ángeles GarcinuñoMiguel García DeltoroCésar HitaJuan Luís Gómez-SirventLuís Buzón2026-03-222026-03-22202210.1016/j.cmi.2022.07.006https://doi.org/10.1016/j.cmi.2022.07.006https://andeanlibrary.org/handle/123456789/45660Citaciones: 18enEmtricitabineHydroxychloroquineMedicinePre-exposure prophylaxisPlaceboCoronavirus disease 2019 (COVID-19)Randomized controlled trialTenofovirSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Double blindDaily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workersarticle